Investigational metabolic peptide

AOD-9604

Prepared by the ezGLP team. Sources last checked September 5, 2026.

Also known as HGH fragment 176-191

Routes represented in the knowledgebase: Subcutaneous (SubQ).

Educational overview

Not FDA-approved. FDA cites limited safety information plus potential immunogenicity, impurity, and serious-adverse-event concerns.

Category: Investigational metabolic peptide
Routes represented: Subcutaneous (SubQ)
Storage context: Follow the dispensed product or pharmacy label; storage and beyond-use time vary by formulation.

Authoritative overview

Published literature

No validated PubMed or DOI link is currently curated for this entry.

Safety evidence

Common or reported: chest tightness, euphoria.

Serious or important: immunogenicity and peptide-impurity concerns.

FDA found that causality for reported serious events could not be assessed and long-term safety is unknown.

Safety evidence source

Summarised from published literature for reference only, with citations to the source. Evidence is graded as reported and is not a recommendation to combine, dose, or use any compound.

For personal tracking and education only. Not medical advice, diagnosis, or treatment, and not a medical device. Peptides may be prescription-only or unapproved where you live — consult a licensed healthcare professional.